Ultragenyx: Fourth Quarter Financial Overview

Ultragenyx Pharmaceutical Reports Fourth Quarter Financial Results

Ultragenyx Pharmaceutical Inc., headquartered in Novato, California, announced on Thursday that it recorded a net loss of $129 million for the fourth quarter.

The company reported a quarterly loss of $1.29 per share.

This performance did not meet the expectations of Wall Street analysts, who, according to a survey by Zacks Investment Research, had predicted an average loss of $1.20 per share.

Despite the loss, Ultragenyx generated $207 million in revenue during the quarter, exceeding the consensus estimate of $202.9 million from seven analysts polled by Zacks.

Financial data for this article was provided by Zacks Investment Research and compiled by Automated Insights.